Dr. William C. Mostertz III, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- Medical University of South Carolina College of Medicine (2016)
- Years since graduation
- 10
- In the NPI registry since
- 2016
- Medicare patients seen, 2024
- 149
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2016Medical school: Medical University of South Carolina College of Medicine
- 2016Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
NC license 2022-01919 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
- Firsthealth Moore Regional Hospital Pinehurst, NC
- Cape Fear Valley Medical Center Fayetteville, NC
- Unc Health Nash Rocky Mount, NC
- Southeastern Regional Medical Center Lumberton, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
- Nhcs Physicians Inc (97 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 149
- Services billed
- 671
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 81 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 62 | 14 |
| Evaluation of lower heart chamber assist device | 59 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 39 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Chapel Hill, NC | 148 |
| Spironolactone Other prescribers in Chapel Hill, NC | 141 |
| Entresto (sacubitril/valsartan) Other prescribers in Chapel Hill, NC | 138 |
| Jardiance (empagliflozin) Other prescribers in Chapel Hill, NC | 100 |
| Warfarin Sodium Other prescribers in Chapel Hill, NC | 58 |
| Torsemide Other prescribers in Chapel Hill, NC | 49 |
| Furosemide Other prescribers in Chapel Hill, NC | 37 |
| Losartan Potassium Other prescribers in Chapel Hill, NC | 35 |
| Vyndamax (tafamidis) | 34 |
| Carvedilol Other prescribers in Chapel Hill, NC | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 24 payments worth $1,268 in total to this clinician.
| Abbott Laboratories | $434 |
|---|---|
| Cvrx, Inc. | $379 |
| Alnylam Pharmaceuticals Inc. | $188 |
| Abiomed | $136 |
| Bridgebio Pharma, Inc. | $43.43 |
| Alexion Pharmaceuticals, Inc. | $39.38 |
| Endotronix, Inc. | $19.26 |
| Pfizer Inc. | $14.15 |
| Food and Beverage | $1,268 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $84,372 in research payments for these studies, mostly to the institutions running them.
- A phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid depleter ALXN2220 in adult participants wiith transthyretin amyloid cardiomyopathy ATTR CM
Alexion Pharmaceuticals, Inc. - NCT06526195--Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Abbott Laboratories - CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. · Completed · NCT04136171 - An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. · Enrolling by invitation · NCT05667493
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.